Analysis of Gefitinib in Human Plasma by Liquid Chromatography-Mass Spectrometry (LC-MS) (CAT#: STEM-CT-1670-CJ)
Introduction
Gefitinib is a treatment for non small cell lung cancer (NSCLC) that has spread into the surrounding tissues (locally advanced) or to other parts of the body.
Liquid chromatography (LC) is a technique widely used to separate compounds from a sample prior to analysis and is frequently coupled to mass spectrometry (MS). With LC, separation of the sample components is based on the interactions of the compounds with the mobile and stationary phases, and the degree of compound separation is related to each compound's affinity for the mobile phase. Following chromatographic separations, compounds elute off of the column, desolvated into the gas phase and ionized at an ionization source, and are then introduced into the mass spectrometer for mass analysis.
1. LC-MS is a dominant analytical technique that has a very high accuracy, sensitivity, and specificity. 2. Although known for its key features in providing rapid analysis of complex mixtures and quality performance, LC-MS is an expensive instrument.